A HS mimetic M402 currently in Phase I/II trials in pancreatic cancer was designed to inhibit tumor-host interactions including VEGF, FGF2, SDF-1 and heparanase [27]. This evidence concerns the gene CXCL12 and familial pancreatic carcinoma.